Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand.
What Happened: The medications cost around $500 monthly for uninsured patients, while insured coverage remains inconsistent across plans. “Coverage is not the same as access,” said Beverly Tchang, a New York-based physician who advises both Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Co. (NYSE:LLY), reported the Associated Press.
